ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0059

Risk Factors for In-Hospital Mortality Among Patients Hospitalized with COVID-19 and AKI

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Grewal, Sahib Daljit Singh, Loma Linda University, Loma Linda, California, United States
  • Abdi Pour, Amir, Loma Linda University, Loma Linda, California, United States
  • Heidari-Bateni, Giv, Loma Linda University, Loma Linda, California, United States
  • Gharibvand, Lida, Loma Linda University, Loma Linda, California, United States
  • Heilbronn, Jackson, Loma Linda University, Loma Linda, California, United States
  • Sharif, Mohammad, Loma Linda University, Loma Linda, California, United States
  • Co, Mita Zahra Estrada, Loma Linda University, Loma Linda, California, United States
  • Agyeman, Kwame B., Loma Linda University, Loma Linda, California, United States
  • Infante, Sergio, Loma Linda University, Loma Linda, California, United States
  • Norouzi, Sayna, Loma Linda University, Loma Linda, California, United States

Group or Team Name

  • Loma Linda Medical Center
Background

Coronavirus disease- 2019 (COVID-19) has the highest mortality in patients with advanced age and those with pre-existing chronic medical conditions. Limited data, however, is available with regard to COVID-19 mortality in acute kidney injury (AKI). We aimed to identify risk factors associated with mortality in patients hospitalized for COVID-19 with AKI.

Methods

This is a retrospective cohort study conducted at Loma Linda University Medical Center (LLUMC) from March 1st, 2020 to January 31st, 2021. Inclusion criteria included patients admitted to LLUMC with diagnosis of COVID-19 and AKI during the admission based on the Risk Injury Failure Loss ESRD (RIFLE) criteria. Univariable and multivariable logistic regression models were utilized to explore risk factors associated with in-hospital mortality.

Results

A total of 320 patients (age 66.5 ± 14.4) were included in the analysis, of which 88 (28%) were deceased. Multivariable regression analysis (Figure 1) demonstrated that age greater than 70 had adjusted odds ratio (OR) with 95% confidence interval (CI) for mortality 1.10 (95% CI: 1.01, 1.20, p=0.03). An Ejection Fraction of less than 50% had OR=1.13 (95% CI: 1.03, 1.23, p=0.01), AKI-injury stage had OR=1.25 (95% CI: 1.14, 1.37, p=<0.001), positive D-dimer levels had OR=1.18 (95% CI: 1.07, 1.30, p=<0.001) and diabetes had OR=1.12 (95% CI 1.03, 1.22, p=0.01), all significant risk factors for mortality. In addition, Hispanics had a higher risk of mortality with OR=1.20 (95% CI 1.09, 1.33, p=<0.001) when compared to Caucasians.

Conclusion

Diabetes, age greater than 70, Hispanic background, Heart failure with reduced ejection fraction, AKI-injury stage, and positive D-dimer level are identified as risk factors associated with higher mortality amongst patient admitted with COVID-19 and AKI.